Novartis Option Fund licenses option on Viamet's metalloenzyme programme

The Novartis Option Fund has signed a licensing option deal with the small US biotechnology firm Viamet Pharmaceuticals.

The Novartis Option Fund has signed a licensing option deal with the small US biotechnology firm Viamet Pharmaceuticals.

Under the agreement, Viamet will use its Metallophile technology to discover and develop novel inhibitors against a specific metalloenzyme of...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip